<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0001635'>Heart failure</z:hpo> patients with stable <z:mp ids='MP_0006112'>angina</z:mp>, <z:hpo ids='HP_0011009'>acute</z:hpo> coronary syndromes and <z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> may benefit from revascularisation and/or valve surgery </plain></SENT>
<SENT sid="1" pm="."><plain>However, the mortality rate is increased- 5-30% </plain></SENT>
<SENT sid="2" pm="."><plain>Biventricular pacing using temporary epicardial wires after surgery is a potential mechanism to improve cardiac function and clinical endpoints </plain></SENT>
<SENT sid="3" pm="."><plain>METHOD/DESIGN: A multi-centred, prospective, randomised, single-blinded, intervention-control trial of temporary biventricular pacing versus standard pacing </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with ischaemic <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo>, <z:hpo ids='HP_0001654'>valvular heart disease</z:hpo> or both, an ejection fraction â‰¤ 35% and a conventional indication for cardiac surgery will be recruited from 2 cardiac centres </plain></SENT>
<SENT sid="5" pm="."><plain>Baseline investigations will include: an electrocardiogram to confirm sinus rhythm and measure QRS duration; echocardiogram to evaluate left ventricular function and markers of mechanical dyssynchrony; dobutamine echocardiogram for viability and blood tests for renal function and biomarkers of myocardial injury- troponin T and brain naturetic <z:chebi fb="7" ids="16670">peptide</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Blood tests will be repeated at 18, 48 and 72 hours </plain></SENT>
<SENT sid="7" pm="."><plain>The principal exclusions will be subjects with permanent atrial <z:hpo ids='HP_0011675'>arrhythmias</z:hpo>, permanent pacemakers, infective <z:hpo ids='HP_0100584'>endocarditis</z:hpo> or <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo>.After surgery, temporary pacing wires will be attached to the postero-lateral wall of the left ventricle, the right atrium and right ventricle and connected to a triple chamber temporary pacemaker </plain></SENT>
<SENT sid="8" pm="."><plain>Subjects will be randomised to receive either temporary biventricular pacing or standard pacing (atrial inhibited pacing or atrial-synchronous right ventricular pacing) for 48 hours.The primary endpoint will be the duration of level 3 care </plain></SENT>
<SENT sid="9" pm="."><plain>In brief, this is the requirement for invasive ventilation, multi-organ support or more than one inotrope/vasoconstrictor </plain></SENT>
<SENT sid="10" pm="."><plain>Haemodynamic studies will be performed at baseline, 6, 18 and 24 hours after surgery using a pulmonary arterial catheter </plain></SENT>
<SENT sid="11" pm="."><plain>Measurements will be taken in the following pacing modes: atrial inhibited; right ventricular only; atrial synchronous-right ventricular; atrial synchronous-left ventricular and biventricular pacing </plain></SENT>
<SENT sid="12" pm="."><plain>Optimisation of the atrioventricular and interventricular delay will be performed in the biventricular pacing group at 18 hours </plain></SENT>
<SENT sid="13" pm="."><plain>The effect of biventricular pacing on myocardial injury, post operative <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> and renal function will also be quantified </plain></SENT>
<SENT sid="14" pm="."><plain>TRIAL REGISTRATION: ClinicalTrials.gov: NCT01027299 </plain></SENT>
</text></document>